In the past week, institutions surveyed nearly 100 individual stocks, with the largest number of Guoxin Health Research institutions. Guoxin Health surveyed 139 institutions, including 31 securities companies, 47 private equity firms, 10 insurance companies, etc. In the survey, the agency asked what is the core reason for the rapid growth of the company's health service business revenue in its semi-annual report. Guoxin Health said it is mainly due to chronic disease management and continued progress in health management business. In the field of health services, the company relies on long-term accumulation in the three medical fields to continuously improve the chronic disease management service system, strengthen supply guarantee, platform support and intelligent service capabilities, and actively promote the integration of AI technology with health service scenarios to improve service efficiency and user experience. Currently, the company continues to advance its chronic disease management business in Shandong, and will continue to improve the refined operation and service capabilities of existing projects. The performance of Fuxiang shares, Bojie shares, Huabao shares, etc. has recently received institutional research. Judging from market performance, institutional research stocks have risen by an average of 0.27% in the past week, with individual stocks such as Shanghai-Nanjing Shares, Yitian Intelligence, and Changcable Technology showing the highest gains.

In the past week, institutions surveyed nearly 100 individual stocks, with the largest number of Guoxin Health Research institutions. Guoxin Health surveyed 139 institutions, including 31 securities companies, 47 private equity firms, 10 insurance companies, etc. In the survey, the agency asked what is the core reason for the rapid growth of the company's health service business revenue in its semi-annual report. Guoxin Health said it is mainly due to chronic disease management and continued progress in health management business. In the field of health services, the company relies on long-term accumulation in the three medical fields to continuously improve the chronic disease management service system, strengthen supply guarantee, platform support and intelligent service capabilities, and actively promote the integration of AI technology with health service scenarios to improve service efficiency and user experience. Currently, the company continues to advance its chronic disease management business in Shandong, and will continue to improve the refined operation and service capabilities of existing projects. The performance of Fuxiang shares, Bojie shares, Huabao shares, etc. has recently received institutional research. Judging from market performance, institutional research stocks have risen by an average of 0.27% in the past week, with individual stocks such as Shanghai-Nanjing Shares, Yitian Intelligence, and Changcable Technology showing the highest gains.